Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 11/20 | 0.37 |
| ▸ | ACACA | Q13085 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18386080 | 0.99 | RARB (0.38) | RARBRARGRXRAPDK2ACACA | |
| SCHEMBL17152099 | 0.93 | RARB (0.38) | RARBRARGRXRAPDK2ACACA | |
| SCHEMBL25680477 | 0.93 | MEN1 (0.38) | RARBRARGRXRAPDK2ACACA | |
| SCHEMBL18386069 | 0.92 | PDK2 (0.40) | RARBRARGRXRAPDK2MEN1 | |
| SCHEMBL17932695 | 0.92 | PDK2 (0.40) | RARBRARGRXRAPDK2MEN1 | |
| SCHEMBL17932701 | 0.92 | MEN1 (0.41) | RARBRARGRXRAPDK2MEN1 | |
| SCHEMBL22115598 | 0.92 | MEN1 (0.41) | RARBRARGRXRAPDK2ACACA | |
| SCHEMBL25533709 | 0.91 | ACACA (0.39) | RARBRARGRXRAPDK2ACACA | |
| SCHEMBL17152101 | 0.91 | RARB (0.38) | RARBRARGRXRAACACAMEN1 | |
| SCHEMBL18386076 | 0.91 | PDK2 (0.39) | PDK2MEN1ALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024114-A1 | ORGANIC LIGHT-EMITTING DEVICE | LG CHEM, LTD. (KR) | 2023-01-26 | — | — | US | disclosed |
| US-10381572-B2 | Heterocyclic compound and organic light-emitting element comprising same | LG CHEM, LTD. (KR) | 2019-08-13 | — | — | US | disclosed |
| US-20170018718-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2017-01-19 | — | — | US | disclosed |
| US-20170018718-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2017-01-19 | — | — | US | disclosed |
| WO-2015152651-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | 주식회사 엘지화학 | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10381572-B2 | Heterocyclic compound and organic light-emitting element comprising same | CRY1, CRY2, PER2 | RARB 350/4885RARG 190/4885RXRA 368/4885 |
| US-20170018718-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, PER2 | RARB 350/4885RARG 190/4885RXRA 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.